September 28, 2017

2020 Formulary Predictions: Get Ahead of the Latest Changes

The months of September and October are filled with anticipation as 2020 commercial and Medicare formularies are revealed. Will the various legislative attempts and successes influence 2020 formulary decisions? Does public outcry of high drug prices and out-of-pocket costs carry weight when managing drug spend is a priority for decision makers? These questions come to mind as we try to surmise whether any formulary surprises are in store for 2020. Todd Edgar assesses how PBMs may react to the current legislative environment; Dan Danielson examines how PBMs influence regional health plans’ 2020 decisions; Elizabeth Oyekan shares the pressure points that influence IDNs and formulary possibilities; and Andrew Cournoyer discusses anticipated Medicare 2020 formulary changes.

I think you’ll find the insights in All Access to be thought provoking and helpful in navigating the payer landscape. As always, please feel free to drop me a note and let me know if you have a topic suggestion for the payer team to address, and we’ll do our best to cover it in a future edition.

Warm Regards,

Charline Shan, RPh, MPH
Vice President, Access Experience Team

All Access is a bimonthly newsletter that features key insights from our team of former payers, intended specifically for market access leaders. It is published by Precision for Value.

Guest Editor
Charline Shan

Executive Editor
Louis Landon

Andrew Cournoyer
Ryan Cox
Dan Danielson
Todd Edgar
Dominic Galante
Ami Gopalan
Joe Honcz
Louis Landon
Elizabeth Oyekan
Jeremy Schafer
Erin Lopata
Kellie Rademacher